70558-16-6

Basic information

• Product Name: 4-(3-CHLORO-PHENYL)-PIPERIDIN-4-OL
• Synonyms: 4-(3-CHLORO-PHENYL)-PIPERIDIN-4-OL;4-(3-CHLOROPHENYL)-4-PIPERIDINOL;4-(3-chlorobenzyl)piperidin-4-ol;4-(3-Chlorophenyl)-4-piperidinol HCl
• CAS NO: 70558-16-6
• Molecular Formula: C₁₁H₁₄ClNO
• Molecular Weight: 211.68796
• Mol File: 70558-16-6.mol
• Article Data: 3

Chemical Properties

• Boiling Point: 356.1±42.0 °C(Predicted)
• Appearance: /
• Density: 1.216±0.06 g/cm3(Predicted)
• PKA: 13.86±0.20(Predicted)
• CAS DataBase Reference: 4-(3-CHLORO-PHENYL)-PIPERIDIN-4-OL(CAS DataBase Reference)
• NIST Chemistry Reference: 4-(3-CHLORO-PHENYL)-PIPERIDIN-4-OL(70558-16-6)
• EPA Substance Registry System: 4-(3-CHLORO-PHENYL)-PIPERIDIN-4-OL(70558-16-6)

Safety Data

• HazardClass: IRRITANT
• Hazardous Substances Data: 70558-16-6(Hazardous Substances Data)

Usage

General Description

4-(3-chloro-phenyl)-piperidin-4-ol is a chemical compound with the molecular formula C11H14ClNO. It is a piperidine derivative with a hydroxyl group attached to the fourth carbon of the piperidine ring and a 3-chloro-phenyl group attached to the fourth carbon. 4-(3-CHLORO-PHENYL)-PIPERIDIN-4-OL has potential pharmaceutical applications due to its structural similarity to other piperidine-based drugs. It may exhibit biological activity as a neurotransmitter modulator or as an analgesic, sedative, or antipsychotic agent. The chemical properties and potential uses of 4-(3-chloro-phenyl)-piperidin-4-ol make it an interesting compound for further research and development in the field of medicinal chemistry.

Upstream product

• 108-37-2 1-bromo-3-chlorobenzene 
• 871112-37-7 tert-butyl 4-(3-chlorophenyl)-4-hydroxypiperidine-1-carboxylate 
• 79099-07-3 N-tert-butyloxycarbonylpiperidin-4-one 

Downstream Products

• 102359-58-0 4-(4-(3-chlorophenyl)-4-hydroxypiperidin-1-yl)-1-(4-fluorophenyl)butan-1-one 
• 1021171-27-6 C₁₉H₂₇ClN₂O₃ 

Relevant articles and documents

Structure-Kinetic Profiling of Haloperidol Analogues at the Human Dopamine D2 Receptor

Haloperidol is a typical antipsychotic drug (APD) associated with an increased risk of extrapyramidal side effects (EPSs) and hyperprolactinemia relative to atypical APDs such as clozapine. Both drugs are dopamine D2 receptor (D2R) antagonists, with contrasting kinetic profiles. Haloperidol displays fast association/slow dissociation at the D2R, whereas clozapine exhibits relatively slow association/fast dissociation. Recently, we have provided evidence that slow dissociation from the D2R predicts hyperprolactinemia, whereas fast association predicts EPS. Unfortunately, clozapine can cause severe side effects independent of its D2R action. Our results suggest an optimal kinetic profile for D2R antagonist APDs that avoids EPS. To begin exploring this hypothesis, we conducted a structure-kinetic relationship study of haloperidol and revealed that subtle structural modifications dramatically change binding kinetic rate constants, affording compounds with a clozapine-like kinetic profile. Thus, optimization of these kinetic parameters may allow development of novel APDs based on the haloperidol scaffold with improved side-effect profiles.

INDOLE DERIVATIVE AND USE FOR TREATMENT OF CANCER

The present invention relates to a compound represented by the formula (I’) wherein A is a benzene ring optionally having substituents, R1, R2a and R3 are each a hydrogen atom, a hydrocarbon group optionally having substituents or a heterocyclic group optionally having substituents, R1 and R2a may form a ring via X, when R1 and R2a form a ring via X, R1 and R2a are each a bond or a divalent C1-5 acyclic hydrocarbon group optionally having substituents, and X is a bond, an oxygen atom, an optionally oxidized sulfur atom or an imino group optionally having a substituent, provided that R1, R2a and X are not bonds at the same time, or a salt thereof, and an agent for inhibiting kinase (phosphorylation enzyme), which contains this compound or a prodrug thereof. The compound of the present invention has an inhibitory activity against kinase such as a vascular endothelial growth factor receptor (VEGFR) and the like, and is useful as an agent for the prophylaxis or threatment of cancer and the like.